Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis

Leukemia

Volumn 26, Issue 4, 2012, Pages 795-805

  Fruchon, S ^a   Kheirallah, S ^a   Al Saati, T ^a   Ysebaert, L ^a   Laurent, C ^a   Leseux, L ^a   Fournie J J ^a   Laurent, G ^a   Bezombes, C ^a  

^a CHU PURPAN   (France)

Author keywords

angiogenesis; follicular lymphoma; fostamatinib; invasion; NHL; Syk

Indexed keywords

FOSTAMATINIB; GELATINASE B; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE SYK; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REGULATION; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, FOLLICULAR; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859635531     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.248     Document Type: Article

References (65)

1. Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108: 4156-4162. (Pubitemid 44913287)
2. Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008; 111: 285-291.
3. Tauzin S, Ding H, Burdevet D, Borisch B, Hoessli DC. Membrane-associated signaling in human B-lymphoma lines. Exp Cell Res 2011; 317: 151-162.
4. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 2010; 15: 517-530.
5. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010; 10: 387-402.
6. Geahlen RL. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim Biophys Acta 2009; 1793: 1115-1127.
7. Schymeinsky J, Sindrilaru A, Frommhold D, Sperandio M, Gerstl R, Then C et al. The Vav binding site of the non-receptor tyrosine kinase Syk at Tyr 348 is critical for beta2 integrin (CD11/CD18)-mediated neutrophil migration. Blood 2006; 108: 3919-3927. (Pubitemid 44864578)
8. Inatome R, Yanagi S, Takano T, Yamamura H. A critical role for Syk in endothelial cell proliferation and migration. Biochem Biophys Res Commun 2001; 286: 195-199. (Pubitemid 32917669)
9. Pearce G, Audzevich T, Jessberger R. SYK regulates B-cell migration by phosphorylation of the F-actin interacting protein SWAP-70. Blood 2011; 117: 1574-1584.
10. Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000; 406: 742-747.
11. Hoeller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R et al. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol 2005; 124: 1293-1299. (Pubitemid 40847418)
12. Wang S, Ding YB, Chen GY, Xia JG, Wu ZY. Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma. World J Gastroenterol 2004; 10: 1815-1818. (Pubitemid 38931212)
13. Mahabeleshwar GH, Kundu GC. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 30-kinase activity in breast cancer cells. J Biol Chem 2003; 278: 6209-6221. (Pubitemid 36800876)
14. Lu J, Lin WH, Chen SY, Longnecker R, Tsai SC, Chen CL et al. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 2006; 281: 8806-8814. (Pubitemid 43847987)
15. Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L et al. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 2007; 67: 7907-7916. (Pubitemid 47281387)
16. Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010; 32: 240-252.
17. Chakraborty G, Rangaswami H, Jain S, Kundu GC. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 2006; 281: 11322-11331. (Pubitemid 43855557)
18. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34. (Pubitemid 43723979)
19. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5: 203-220. (Pubitemid 40694861)
20. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
21. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. (Pubitemid 36749215)
22. Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009; 20: 413-424.
23. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893-2902. (Pubitemid 39434977)
24. Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003; 39: 1948-1956. (Pubitemid 37311193)
25. Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996; 2: 1411-1416. (Pubitemid 26299442)
26. Hazar B, Polat G, Seyrek E, Bagdatoglglu O, Kanik A, Tiftik N. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma. Int J Clin Pract 2004; 58: 139-143. (Pubitemid 38425743)
27. Kossakowska AE, Urbanski SJ, Janowska-Wieczorek A. Matrix metalloproteinases and their tissue inhibitors - expression, role and regulation in human malignant non-Hodgkin's lymphomas. Leuk Lymphoma 2000; 39: 485-493. (Pubitemid 32162388)
28. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712-3718.
29. Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem 1999; 274: 32662-32666. (Pubitemid 129535293)
30. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)- 4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-5532.
31. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010; 38: 1436-1442.
32. Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma. Eur J Haematol 2008; 81: 289-297.
33. Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Ostenstad B et al. Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50: 998-1004.
34. Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RJ, Hammer AS et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 2007; 170: 1362-1369. (Pubitemid 47339342)
35. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135. (Pubitemid 34155123)
36. Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009; 113: 2508-2516.
37. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006; 319: 998-1008.
38. Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 2004; 100: 356-365. (Pubitemid 38063646)
39. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009; 114: 1029-1037.
40. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009; 39: 177-186.
41. Han S, Ritzenthaler JD, Sitaraman SV, Roman J. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. J Biol Chem 2006; 281: 29614-29624. (Pubitemid 44536969)
42. Jiang K, Zhong B, Ritchey C, Gilvary DL, Hong-Geller E, Wei S et al. Regulation of Akt-dependent cell survival by Syk and Rac. Blood 2003; 101: 236-244. (Pubitemid 36025913)
43. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007; 26: 611-621. (Pubitemid 350115107)
44. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews 2002; 2: 489-501. (Pubitemid 37328931)
45. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev 2004; 4: 335-348. (Pubitemid 38579480)
46. Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010; 2010: 265-270.
47. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2010; 25: 341-347.
48. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev 2009; 9: 550-562.
49. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010; 24: 1781-1784.
50. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740-4746.
51. Garcia-Martinez JM, Wullschleger S, Preston G, Guichard S, Fleming S, Alessi DR et al. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer 2011; 104: 1116-1125.
52. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010; 123: 1007-1013.
53. Coffey GP, Rajapaksa R, Liu R, Sharpe O, Kuo CC, Krauss SW et al. Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J Cell Sci 2009; 122: 3137-3144.
54. Iiizumi M, Bandyopadhyay S, Pai SK, Watabe M, Hirota S, Hosobe S et al. RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 2008; 68: 7613-7620.
55. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65: 2406-2411. (Pubitemid 40490152)
56. Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML et al. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem 2005; 280: 1543-1551.
57. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004; 279: 45643-45651. (Pubitemid 39491552)
58. Bradbury D, Clarke D, Seedhouse C, Corbett L, Stocks J, Knox A. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 2005; 280: 29993-30000. (Pubitemid 41216174)
59. Wang L, Devarajan E, He J, Reddy SP, Dai JL. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res 2005; 65: 10289-10297. (Pubitemid 41743721)
60. Chetty C, Lakka SS, Bhoopathi P, Rao JS. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 2010; 127: 1081-1095.
61. Belotti D, Calcagno C, Garofalo A, Caronia D, Riccardi E, Giavazzi R et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 2008; 6: 525-534. (Pubitemid 351521834)
62. Labidi SI, Menetrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T et al. Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival. Ann Hematol 2009; 89: 25-33.
63. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111: 2230-2237. (Pubitemid 351451430)
64. Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115: 4497-4506.
65. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.